article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59
article thumbnail

Novartis knocked back again in bid to block Gilenya generics in US

pharmaphorum

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. After initially upholding the patent in January, the CAFC subsequently ruled in June that it was not valid, opening the door to low-cost competition to Novartis’ third biggest-selling product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

The landscape is highly competitive with new prescription medications launching worldwide each year. Early shaping of the label during clinical trial design, risk mitigation, and avoiding approval delays are crucial for seizing a competitive advantage.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Observational studies should not be seen as competition to RCTs but as complementary to them, and as a sector we need to stop working in silos and develop an integrated and more comprehensive approach to evidence-based decision-making in safeguarding public health. EMA/95098/2010. Internet] European Medicines Agency. cited Dec2023].

Medicine 116
article thumbnail

Supreme court throws Novartis a lifeline for Gilenya defense

pharmaphorum

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Gilenya made revenues of $2.8 Sales in the first half of this year fell 19% to $1.16

article thumbnail

470% price increases

World of DTC Marketing

According to AbbVie’s internal data, the company collected nearly $10 billion in Humira net revenue from Medicare Part D between 2010 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. Lack of Medicare Negotiation Costing Taxpayers Billions: U.S.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. Over the same period, similar countries – including Ireland, France, and Germany – have been moving to boosting manufacturing productivity, output, and exports.